HRP20121052T1 - Medikament za perioperativnu terapiju äśvrstih tumora u dva koraka radioimunoterapijom - Google Patents
Medikament za perioperativnu terapiju äśvrstih tumora u dva koraka radioimunoterapijom Download PDFInfo
- Publication number
- HRP20121052T1 HRP20121052T1 HRP20121052TT HRP20121052T HRP20121052T1 HR P20121052 T1 HRP20121052 T1 HR P20121052T1 HR P20121052T T HRP20121052T T HR P20121052TT HR P20121052 T HRP20121052 T HR P20121052T HR P20121052 T1 HRP20121052 T1 HR P20121052T1
- Authority
- HR
- Croatia
- Prior art keywords
- avidin
- agent
- use according
- group
- derivatives
- Prior art date
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
- A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
- A61K47/6898—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies using avidin- or biotin-conjugated antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Nanotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Claims (10)
1. Upotreba prvog sredstva koje posjeduje tumorski tropizam, kojeg se bira iz skupine koju čine avidin, streptavidin, njihovi polimerni derivati i njihovi derivati s polietilen-glikolom, u kombinaciji s drugim sredstvom protiv raka, koje posjeduje afinitet za navedeno prvo sredstvo, kojeg čini biotinski spoj, koji nosi sredstvo protiv raka kao aktivne sastojke za pripravu medikamenta korisnog u perioperativnoj terapiji čvrstih tumora u dva koraka, naznačena time što se navedeno prvo sredstvo lokoregionalno primijenjuje za vrijeme intraoperativnog koraka, a navedeno drugo sredstvo se sistemno primijenjuje za vrijeme postoperativnog koraka.
2. Upotreba u skladu s patentnim zahtjevom 1, naznačena time što se navedeno sredstvo protiv raka bira iz skupine koju čine radioizotopi, kemoterapijska sredstva, toksini i antitumorske stanice.
3. Upotreba u skladu s patentnim zahtjevom 2, naznačena time što se navedeni radioizotop bira iz skupine koju čine Fe-52, Mn-52m, Co-55, Cu-64, Ga-67, Ga-68, Tc-99m, In-111, I-123, I-125, I-131, P-32, Sc-47, Cu-67, Y-90, Pd-109, Ag-111, I-131, Pm-149, Re-186, Re-188, At-211, Pb-212, Bi-212, te Lu-177.
4. Upotreba u skladu s patentnim zahtjevom 3, naznačena time što je navedeni radioizotop Y-90 ili Lu-177.
5. Upotreba u skladu s patentnim zahtjevom 1, naznačena time što su avidinski i biotinski spoj u navedenom medikamentu u odvojenim spremnicima.
6. Upotreba u skladu s bilo kojim od od prethodnih patentnih zahtjeva, naznačena time što se navedeni tumor bira iz skupine koju čine tumori dojke, gušterače, pluća, poplućnice, potrbušnice, vrata i lica, mozga i mokraćnog mjehura.
7. Upotreba u skladu s bilo kojim od od prethodnih patentnih zahtjeva, naznačena time što je navedeni medikament pogodan za primjenu injekcijom.
8. Upotreba u skladu s patentnim zahtjevom 5, naznačena time što je spremnik navedenog avidina u obliku injekcijske šprice, pogodne za uzastopne primjene točno određenih volumena.
9. Upotreba u skladu s patentnim zahtjevom 1, naznačena time što se navedeni avidin nalazi u odvojenom spremniku u jednoj dozi.
10. Komplet namijenjen upotrebi u perioperativnoj terapiji u dva koraka u skladu s patentnim zahtjevom 1, naznačen time što sadrži više odvojenih spremnika, gdje prvi spremnik sadrži avidinski spoj, kojeg se bira iz skupine koju čine avidin, streptavidin, njihovi polimerni derivati i njihovi derivati s polietilen-glikolom, a drugi spremnik sadrži biotinski spoj, koji nosi sredstvo protiv raka.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT000196A ITRM20030196A1 (it) | 2003-04-24 | 2003-04-24 | Uso di reagenti per la preparazione di un medicamento |
| PCT/IT2004/000184 WO2004093916A1 (en) | 2003-04-24 | 2004-04-07 | A medicament for the two-step perioperative therapy of solid tumours |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HRP20121052T1 true HRP20121052T1 (hr) | 2013-01-31 |
| HRP20121052T8 HRP20121052T8 (en) | 2013-03-31 |
Family
ID=29765781
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20121052TT HRP20121052T8 (en) | 2003-04-24 | 2004-04-07 | A medicament for the two-step perioperative therapy of solid tumours by radioimmunotherapy |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US7935346B2 (hr) |
| EP (1) | EP1615668B1 (hr) |
| JP (1) | JP4949016B2 (hr) |
| KR (1) | KR20060005383A (hr) |
| CN (1) | CN1777446A (hr) |
| AR (1) | AR044052A1 (hr) |
| AU (1) | AU2004231377B2 (hr) |
| BR (1) | BRPI0409604A (hr) |
| CA (1) | CA2522580C (hr) |
| CY (1) | CY1113488T1 (hr) |
| DK (1) | DK1615668T3 (hr) |
| ES (1) | ES2398389T3 (hr) |
| HR (1) | HRP20121052T8 (hr) |
| IT (1) | ITRM20030196A1 (hr) |
| MX (1) | MXPA05011293A (hr) |
| PL (1) | PL1615668T3 (hr) |
| PT (1) | PT1615668E (hr) |
| SI (1) | SI1615668T1 (hr) |
| TW (1) | TWI368518B (hr) |
| WO (1) | WO2004093916A1 (hr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITRM20030196A1 (it) | 2003-04-24 | 2004-10-25 | Sigma Tau Ind Farmaceuti | Uso di reagenti per la preparazione di un medicamento |
| SG183076A1 (en) * | 2007-08-02 | 2012-08-30 | Sigma Tau Ind Farmaceuti | Oxidized avidin with high residency time in the treated tissues |
| IT1398977B1 (it) | 2009-06-25 | 2013-03-28 | Icgeb | Agente anticancro specifico per i tumori cerebrali con meccanismo di soppressione di recq1 |
| WO2013017494A1 (en) * | 2011-08-02 | 2013-02-07 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Pharmaceutical composition of oxidised avidin suitable for inhalation |
| US20160331853A1 (en) * | 2014-01-21 | 2016-11-17 | The Trustees Of Columbia University In The City Of New York | Compositions for radiotherapy and uses thereof |
| WO2017003908A1 (en) | 2015-06-30 | 2017-01-05 | The Trustees Of Columbia University In The City Of New York | Talc-bound compositions and uses thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4863713A (en) | 1986-06-23 | 1989-09-05 | The Board Of Trustees Of Leland Stanford Jr. Univ. | Method and system for administering therapeutic and diagnostic agents |
| US6054122A (en) * | 1990-11-27 | 2000-04-25 | The American National Red Cross | Supplemented and unsupplemented tissue sealants, methods of their production and use |
| IT1245748B (it) * | 1990-12-21 | 1994-10-14 | Mini Ricerca Scient Tecnolog | Preparazione includente anticorpi monoclonali biotinilati, avidina e biotina, per la diagnosi di affezioni tumorali e suo impiego |
| US6096289A (en) * | 1992-05-06 | 2000-08-01 | Immunomedics, Inc. | Intraoperative, intravascular, and endoscopic tumor and lesion detection, biopsy and therapy |
| EP1346730A1 (en) | 1993-12-07 | 2003-09-24 | Neorx Corporation | Pretargeting methods and novel pretargeting conjugates |
| ITRM20010079A1 (it) | 2001-02-16 | 2002-08-16 | Sigma Tau Ind Farmaceuti | Amminoderivati della biotina e loro coniugati con chelanti macrociclici. |
| CA2449941A1 (en) | 2001-06-11 | 2002-12-19 | University Of Miami | Use of radiopharmaceutical complexes in achieving transplantation tolerance |
| ITRM20020071A1 (it) | 2002-02-11 | 2003-08-11 | Sigma Tau Ind Farmaceuti | Contenitore per flacone di radiofarmaco, e corredo per la sua infusione in un paziente o per il suo trasferimento altrove. |
| US20030228256A1 (en) | 2002-06-11 | 2003-12-11 | Inverardi Luca A. | Methods of achieving transplantation tolerance through radioablation of hemolymphopoietic cell populations |
| ITRM20030196A1 (it) | 2003-04-24 | 2004-10-25 | Sigma Tau Ind Farmaceuti | Uso di reagenti per la preparazione di un medicamento |
-
2003
- 2003-04-24 IT IT000196A patent/ITRM20030196A1/it unknown
-
2004
- 2004-04-07 WO PCT/IT2004/000184 patent/WO2004093916A1/en not_active Ceased
- 2004-04-07 PT PT47262498T patent/PT1615668E/pt unknown
- 2004-04-07 PL PL04726249T patent/PL1615668T3/pl unknown
- 2004-04-07 KR KR1020057019995A patent/KR20060005383A/ko not_active Ceased
- 2004-04-07 SI SI200431974T patent/SI1615668T1/sl unknown
- 2004-04-07 CA CA2522580A patent/CA2522580C/en not_active Expired - Fee Related
- 2004-04-07 DK DK04726249.8T patent/DK1615668T3/da active
- 2004-04-07 JP JP2006507647A patent/JP4949016B2/ja not_active Expired - Fee Related
- 2004-04-07 MX MXPA05011293A patent/MXPA05011293A/es active IP Right Grant
- 2004-04-07 HR HRP20121052TT patent/HRP20121052T8/hr unknown
- 2004-04-07 EP EP04726249A patent/EP1615668B1/en not_active Expired - Lifetime
- 2004-04-07 ES ES04726249T patent/ES2398389T3/es not_active Expired - Lifetime
- 2004-04-07 BR BRPI0409604-5A patent/BRPI0409604A/pt not_active IP Right Cessation
- 2004-04-07 US US10/554,410 patent/US7935346B2/en not_active Expired - Fee Related
- 2004-04-07 CN CNA200480010867XA patent/CN1777446A/zh active Pending
- 2004-04-07 AU AU2004231377A patent/AU2004231377B2/en not_active Ceased
- 2004-04-12 TW TW093110125A patent/TWI368518B/zh not_active IP Right Cessation
- 2004-04-22 AR ARP040101356A patent/AR044052A1/es not_active Application Discontinuation
-
2012
- 2012-12-14 CY CY20121101221T patent/CY1113488T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2398389T3 (es) | 2013-03-15 |
| SI1615668T1 (sl) | 2013-01-31 |
| US7935346B2 (en) | 2011-05-03 |
| WO2004093916A8 (en) | 2005-11-03 |
| AU2004231377B2 (en) | 2010-08-05 |
| CN1777446A (zh) | 2006-05-24 |
| US20060251579A1 (en) | 2006-11-09 |
| CY1113488T1 (el) | 2016-06-22 |
| JP2006524235A (ja) | 2006-10-26 |
| EP1615668A1 (en) | 2006-01-18 |
| EP1615668B1 (en) | 2012-12-05 |
| PL1615668T3 (pl) | 2013-03-29 |
| BRPI0409604A (pt) | 2006-04-18 |
| ITRM20030196A0 (it) | 2003-04-24 |
| CA2522580C (en) | 2013-08-06 |
| ITRM20030196A1 (it) | 2004-10-25 |
| PT1615668E (pt) | 2013-01-14 |
| HRP20121052T8 (en) | 2013-03-31 |
| JP4949016B2 (ja) | 2012-06-06 |
| WO2004093916A1 (en) | 2004-11-04 |
| KR20060005383A (ko) | 2006-01-17 |
| TW200501984A (en) | 2005-01-16 |
| AU2004231377A1 (en) | 2004-11-04 |
| CA2522580A1 (en) | 2004-11-04 |
| AR044052A1 (es) | 2005-08-24 |
| TWI368518B (en) | 2012-07-21 |
| DK1615668T3 (da) | 2013-02-04 |
| MXPA05011293A (es) | 2006-01-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7011812B1 (en) | Targeted combination immunotherapy of cancer and infectious diseases | |
| FI3682907T3 (fi) | Radiomerkityn nanoaineen käyttö syövän prognoosissa ja diagnoosissa | |
| US6077499A (en) | Targeted combination immunotherapy of cancer | |
| US7514066B2 (en) | Targeted combination immunotherapy of cancer and infectious diseases | |
| Goodwin et al. | Advances in pretargeting biotechnology | |
| Yoshimoto et al. | αvβ3 Integrin‐targeting radionuclide therapy and imaging with monomeric RGD peptide | |
| Rusckowski et al. | Pretargeting using peptide nucleic acid | |
| HRP20121052T1 (hr) | Medikament za perioperativnu terapiju äśvrstih tumora u dva koraka radioimunoterapijom | |
| CN105451780B (zh) | 放射性标记材料 | |
| HRP20170735T1 (hr) | Oksidirani avidin s dugim trajanjem zadržavanja u obrađenim tkivima | |
| WO2003101496A1 (en) | Methods and compositions for intravesical therapy of bladder cancer | |
| JP2006524235A5 (hr) | ||
| JP2010535166A5 (hr) | ||
| JP2020504106A5 (hr) | ||
| Liu et al. | Successful radiotherapy of tumor in pretargeted mice by 188Re-radiolabeled phosphorodiamidate morpholino oligomer, a synthetic DNA analogue | |
| JP2006511532A (ja) | 三官能性試薬によって連結された、エフェクター機能および親和性機能を有する抗リンパ腫ターゲティング剤 | |
| Arano | Strategies to reduce renal radioactivity levels of antibody fragments | |
| Bal et al. | Theranostic in glioblastoma | |
| Sheets et al. | Radioisotopes and nanomedicine | |
| Mohsin | Macromolecular radiopharmaceuticals | |
| JP2005535676A5 (hr) | ||
| WO1995033491B1 (en) | Biotin compounds for targetting tumors and sites of infection | |
| JP2006523706A (ja) | 増幅ターゲッティングによるモルホリノイメージングおよび治療 | |
| GT199700143A (es) | Forma de dosificacion farmaceutica que enmascara el sabor y que se libera rapidamente. |